M
MYLAN IRELAND C/O ALLOGA RDC
Siegfried AG was founded in 1873. This company provides the research and manufacturing of pharmaceuticals. Their headquarters are located in Aargau, Switzerland.
Country/Area ：Ireland
Company Email ：hr@siegfried.ch
Industry ：BeautyManufacturing GeneralManufacturingHome Appliances
Company address ：4 Untere Brühlstrasse, Zofingen, Aargau, 4800, Switzerland
Company website ：*****
Company phone ：+41 627461111
Established ：1873
Company Revenue ：$1,150,754,000
Number of employees ：3338
SIC Code ：28283
NAICS Code ：32325
Main Products ：Oral solidsInhalation productsSterilesOphthalmics
Company News
Institutions own 44% of Siegfried Holding AG (VTX:SFZN) shares but retail investors control 45% of the company
Oct 13, 2023
Key Insights Siegfried Holding's significant retail investors ownership suggests that the key decisions are influenced...
Oct 13, 2023
Siegfried Holding AG's (VTX:SFZN) Intrinsic Value Is Potentially 25% Below Its Share PriceAug 20, 2023
Key Insights Siegfried Holding's estimated fair value is CHF588 based on 2 Stage Free Cash Flow to Equity Siegfried...
Aug 20, 2023Those who invested in Siegfried Holding (VTX:SFZN) five years ago are up 89%Jun 8, 2023
When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...
Jun 8, 2023Are Robust Financials Driving The Recent Rally In Siegfried Holding AG's (VTX:SFZN) Stock?May 23, 2023
Siegfried Holding (VTX:SFZN) has had a great run on the share market with its stock up by a significant 8.5% over the...
May 23, 2023Web Summary
Q1: What is the address of Mylan Ireland C/O Alloga RDC?
A1: The address of Mylan Ireland C/O Alloga RDC is not explicitly mentioned in the provided text, but it can be inferred that they are based in Switzerland as their headquarters is located in Zofingen, Switzerland.
Q2: What products does Mylan Ireland C/O Alloga RDC offer?
A2: According to the text, Mylan Ireland C/O Alloga RDC develops and manufactures APIs (Active Pharmaceutical Ingredients) and their intermediates as well as drug products for the pharmaceutical industry.
Q3: In which industries is Mylan Ireland C/O Alloga RDC involved?
A3: The provided text does not explicitly mention the specific industries in which Mylan Ireland C/O Alloga RDC operates. However, it can be inferred that they are involved in the pharmaceutical industry, as they develop and manufacture APIs and drug products.
Q4: What services does Mylan Ireland C/O Alloga RDC provide?
A4: According to the text, Mylan Ireland C/O Alloga RDC offers a comprehensive range of services from process development and optimization to registration, production, packaging, and logistics, addressing the challenges of the outsourcing trend in the pharmaceutical industry.
Q5: What is the purpose of Siegfried's EVOLVE + strategy?
A5: The purpose of Siegfried's EVOLVE + strategy is to bolster their position as a leading global integrated provider of development and manufacturing services. It aims to expand their core business, grow new areas, broaden their range of technologies and services, sharpen focus on commercial, development, and operational excellence, and accelerate profitable growth.
Q6: What are the key trends driving Siegfried's sustainable business model?
A6: The key trends driving Siegfried's sustainable business model include pharmaceutical companies increasingly outsourcing manufacturing to focus on R&D and marketing and distribution, the need for flexible production, the increased importance of small and medium-sized pharmaceutical players, the complexity of the pharmaceutical supply chain, and proactive lifecycle management.
Q7: How does Mylan Ireland C/O Alloga RDC adapt their manufacturing portfolio to meet changing demand patterns?
A7: According to the text, large-scale, diversified CDMOs like Siegfried can adapt their manufacturing portfolio more flexibly to the needs of their customers, which is particularly beneficial for innovative pharmaceutical companies facing complex development and manufacturing challenges.
Q8: What is the location of Mylan Ireland C/O Alloga RDC's production sites?
A8: The text mentions that Siegfried has production sites in Switzerland, the USA, Malta, China, Germany, France, and Spain. However, it does not specifically mention Mylan Ireland C/O Alloga RDC as having separate production sites.
A1: The address of Mylan Ireland C/O Alloga RDC is not explicitly mentioned in the provided text, but it can be inferred that they are based in Switzerland as their headquarters is located in Zofingen, Switzerland.
Q2: What products does Mylan Ireland C/O Alloga RDC offer?
A2: According to the text, Mylan Ireland C/O Alloga RDC develops and manufactures APIs (Active Pharmaceutical Ingredients) and their intermediates as well as drug products for the pharmaceutical industry.
Q3: In which industries is Mylan Ireland C/O Alloga RDC involved?
A3: The provided text does not explicitly mention the specific industries in which Mylan Ireland C/O Alloga RDC operates. However, it can be inferred that they are involved in the pharmaceutical industry, as they develop and manufacture APIs and drug products.
Q4: What services does Mylan Ireland C/O Alloga RDC provide?
A4: According to the text, Mylan Ireland C/O Alloga RDC offers a comprehensive range of services from process development and optimization to registration, production, packaging, and logistics, addressing the challenges of the outsourcing trend in the pharmaceutical industry.
Q5: What is the purpose of Siegfried's EVOLVE + strategy?
A5: The purpose of Siegfried's EVOLVE + strategy is to bolster their position as a leading global integrated provider of development and manufacturing services. It aims to expand their core business, grow new areas, broaden their range of technologies and services, sharpen focus on commercial, development, and operational excellence, and accelerate profitable growth.
Q6: What are the key trends driving Siegfried's sustainable business model?
A6: The key trends driving Siegfried's sustainable business model include pharmaceutical companies increasingly outsourcing manufacturing to focus on R&D and marketing and distribution, the need for flexible production, the increased importance of small and medium-sized pharmaceutical players, the complexity of the pharmaceutical supply chain, and proactive lifecycle management.
Q7: How does Mylan Ireland C/O Alloga RDC adapt their manufacturing portfolio to meet changing demand patterns?
A7: According to the text, large-scale, diversified CDMOs like Siegfried can adapt their manufacturing portfolio more flexibly to the needs of their customers, which is particularly beneficial for innovative pharmaceutical companies facing complex development and manufacturing challenges.
Q8: What is the location of Mylan Ireland C/O Alloga RDC's production sites?
A8: The text mentions that Siegfried has production sites in Switzerland, the USA, Malta, China, Germany, France, and Spain. However, it does not specifically mention Mylan Ireland C/O Alloga RDC as having separate production sites.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
